An entry point to the field of neurogenetics — how inherited and de novo genetic variants cause neurological disease, the spectrum of neurogenetic disorders, and the clinical framework for evaluating a patient with a suspected genetic neurological condition.
Tags: Neurogenetics · Basic Genetics
Neurogenetics is the study of how genetic variation — inherited or arising de novo — contributes to neurological disease. As a clinical discipline it bridges neurology and medical genetics, encompassing diagnosis, genetic counseling, and an increasingly robust landscape of mechanism-targeted therapies. The importance of neurogenetics has grown dramatically with next-generation sequencing: roughly 50% of pediatric-onset epilepsies, 30–40% of childhood intellectual disabilities, and a significant fraction of early-onset movement disorders and neurodegenerative diseases now have identifiable genetic causes.
Key Points
Neurological diseases span a continuum of genetic architecture: from fully penetrant Mendelian single-gene disorders to complex polygenic traits modulated by environmental exposures. Understanding which architecture applies to a given condition guides testing strategy, interpretation, and counseling. Most severe early-onset neurological conditions have a monogenic basis; common late-onset conditions (Alzheimer disease, Parkinson disease) are predominantly polygenic with rare high-penetrance variants in a subset of patients.
Key Points
Neurogenetic diseases are conventionally grouped by clinical phenotype, although the same gene can cause multiple phenotypes (pleiotropy) and the same phenotype can result from variants in many genes (genetic heterogeneity). Knowing the most common neurogenetic disease categories and their prototypical genes equips clinicians to build focused differential diagnoses.
Key Points
The genetic evaluation begins with a structured history and examination tailored to identify patterns suggestive of an inherited or de novo neurological disorder. A three-generation pedigree is the cornerstone of genetic assessment and can often reveal the mode of inheritance before any test is ordered. Distinctive features, multi-system involvement, and characteristic neuroimaging patterns guide both the differential diagnosis and the choice of genetic test.
Key Points
The choice of genetic test should be guided by the clinical phenotype, suspected genetic architecture, and available resources. Modern sequencing has shifted practice toward comprehensive 'first-line' tests (chromosomal microarray, exome sequencing) in many settings, while targeted tests remain appropriate when the differential is narrow. Understanding test capabilities and limitations is essential for ordering the right test and interpreting results.
Key Points
1. A 3-year-old boy presents with global developmental delay, no family history, and no distinctive features. Chromosomal microarray and fragile X testing are normal. What is the most appropriate next step?
When chromosomal microarray (which detects CNVs) and targeted tests (fragile X) are non-diagnostic, exome or genome sequencing is the recommended next step for unexplained intellectual disability/developmental delay. The diagnostic yield is ~30–40%, identifying pathogenic variants in known disease genes. Karyotype detects balanced rearrangements but has much lower resolution than CMA and adds limited yield after a normal microarray.
2. Which of the following best describes 'de novo' variants in the context of neurogenetic disease?
De novo variants arise spontaneously during gametogenesis or early embryogenesis and are not inherited from either parent (confirmed by parental testing). They disproportionately cause severe early-onset neurological conditions because they are not subject to negative selection across generations. Classic examples include SCN1A variants in Dravet syndrome, KCNQ2 variants in neonatal epileptic encephalopathy, and MECP2 variants in Rett syndrome.
3. A child is found to have tuberous sclerosis complex (TSC) with subependymal nodules, ash-leaf macules, and focal epilepsy. The molecular cause is most likely:
Tuberous sclerosis complex is caused by pathogenic variants in TSC1 (hamartin) or TSC2 (tuberin), both of which are negative regulators of the mTOR (mechanistic target of rapamycin) signaling pathway. Loss-of-function variants lead to uncontrolled mTOR activation, causing benign hamartomas in multiple organ systems. TSC follows autosomal dominant inheritance; ~70% of cases arise de novo. mTOR inhibitors (everolimus, sirolimus) are approved treatments for TSC-associated manifestations.
4. When taking a family history for a child with suspected autosomal recessive neurogenetic disease, which pedigree feature is most informative?
In autosomal recessive (AR) disease, affected individuals are typically in a single sibship (horizontal pedigree pattern), with both parents as unaffected carriers. An affected sibling with the same phenotype is the most informative AR pedigree finding. Consanguinity (shared ancestors in the parents) also strongly supports AR inheritance. In contrast, affected parent-to-child transmission suggests autosomal dominant, and exclusively affected males through the maternal line is the hallmark of X-linked recessive inheritance.
5. Fragile X syndrome is the most common inherited cause of intellectual disability in males. What is its molecular mechanism?
Fragile X syndrome is caused by expansion of a CGG trinucleotide repeat in the 5' untranslated region of the FMR1 gene (Xq27.3). Full mutations (>200 repeats) lead to hypermethylation and transcriptional silencing of FMR1, resulting in absent FMRP protein. FMRP is an mRNA-binding protein critical for synaptic plasticity. Normal alleles have 5–44 repeats; premutation alleles (55–200 repeats) do not silence the gene but can cause FXTAS (fragile X-associated tremor/ataxia syndrome) in older carrier males.